PT-141 / Bremelanotide
Bremelanotide—originally developed as PT-141—is the active drug in Vyleesi®, an FDA-approved, as-needed treatment for acquired, generalized hypoactive sexual desire disorder in certain premenopausal women.
What makes bremelanotide particularly interesting is that it approaches sexual wellness through the brain and melanocortin system rather than acting primarily as a hormone therapy or peripheral vasodilator.
FDA-Approved as Vyleesi® • Nonhormonal • As-Needed TreatmentWhat Is PT-141?
PT-141 is commonly used to refer to bremelanotide, a synthetic cyclic peptide that activates melanocortin receptors.
The FDA-approved pharmaceutical formulation is marketed as Vyleesi®.
Unlike therapies that primarily focus on hormone replacement or genital blood flow, bremelanotide targets signaling within the central nervous system and was developed specifically around sexual-desire biology.
Sexual Desire Is a Whole-System Process
Sexual desire reflects the interaction of brain signaling, hormones, stress, emotional health, relationship context, medications, sleep, physical health, and sensory input.
Desire & Motivation
Brain networks involved in motivation, reward, attention, and sexual cues contribute to the experience of desire.
Brain Signaling
Central nervous system pathways integrate emotional, sensory, behavioral, and physiologic information.
Hormonal Environment
Estrogen, testosterone, thyroid function, prolactin, menopause, and other endocrine factors may influence libido.
Physical Health
Cardiovascular health, pain, sleep, medications, neurologic function, and metabolic health can all affect sexual wellness.
Low Desire Is Not the Same as Sexual Performance
A person may have normal physical sexual function but little desire—or strong desire with impaired physical arousal. Determining which part of the system is affected matters.
How Does Bremelanotide Work?
Bremelanotide activates several members of the melanocortin receptor family.
At therapeutic exposure, FDA identifies MC1R and MC4R as the most relevant receptor interactions.
MC4R — Central Nervous System
MC4 receptors are found throughout multiple areas of the brain. Melanocortin signaling within these networks is involved in behavior, motivation, energy regulation, and pathways relevant to sexual desire and arousal.
MC1R — Pigmentation
MC1 receptors are found on melanocytes. Activation can increase melanin expression, which explains why focal hyperpigmentation can occur with bremelanotide.
What We Know—and What We Don’t
The melanocortin system clearly plays an important role in the drug’s pharmacology. However, FDA prescribing information states that the exact mechanism by which Vyleesi improves HSDD remains unknown.
FDA-Approved Use
Acquired, Generalized Hypoactive Sexual Desire Disorder
Vyleesi is FDA approved for premenopausal women with acquired, generalized HSDD when low sexual desire causes marked distress or interpersonal difficulty.
The low desire must not be explained by a co-existing medical or psychiatric condition, relationship problem, medication, or another drug substance.
What Does “Acquired, Generalized” Mean?
Acquired means the problem developed after a period in which sexual desire was not problematic.
Generalized means the low desire occurs regardless of the type of stimulation, situation, or sexual partner.
Limitations of the FDA Approval
Vyleesi is not FDA indicated for postmenopausal women, men, or simply to enhance sexual performance.
What Did the Clinical Trials Show?
The pivotal RECONNECT program included two nearly identical randomized, double-blind, placebo-controlled Phase 3 trials.
A total of 1,267 women were randomized, with 1,247 included in the safety population.
Increased Sexual Desire
Both Phase 3 studies demonstrated statistically significant improvements in the Female Sexual Function Index desire score compared with placebo.
Reduced Distress
Bremelanotide significantly reduced the degree to which women were bothered by low sexual desire compared with placebo.
Sustained Research
A 52-week open-label extension found sustained improvement in HSDD symptoms without new safety signals emerging during the extension.
The Clinical Goal
The key outcomes were not simply “more sex.” The trials focused on whether women experienced greater sexual desire and less distress about low desire.
An Important Research Detail
The pivotal FDA analysis did not find a significant difference between Vyleesi and placebo in the change in number of satisfying sexual events. The demonstrated benefit centered on desire and distress.
How Is FDA-Approved Vyleesi Used?
FDA-Labeled Administration
The approved Vyleesi autoinjector delivers 1.75 mg subcutaneously into the abdomen or thigh at least 45 minutes before anticipated sexual activity.
FDA labeling states that patients should not use more than one dose within 24 hours and that more than eight doses per month is not recommended.
The Timing Is Individual
FDA notes that the optimal treatment window has not been fully characterized. Patients using the approved product may determine timing based on their own experience with benefit and adverse effects.
Evaluate Whether It Is Actually Helping
The prescribing information recommends discontinuing Vyleesi after eight weeks if the patient does not report improvement in symptoms.
Safety & Important Considerations
Nausea
The most common adverse reaction. In Phase 3 trials it occurred in approximately 40% of Vyleesi-treated patients.
Flushing
Flushing occurred in approximately 20% of treated patients in the controlled clinical trials.
Injection-Site Reactions
Local pain, redness, bruising, itching, or other injection-site reactions occurred in approximately 13%.
Headache
Headache occurred in approximately 11% of treated patients.
Blood Pressure
Bremelanotide can temporarily increase blood pressure and reduce heart rate after administration.
Hyperpigmentation
Focal darkening of areas including the face, gums, and breasts has been reported and may not completely resolve in every patient.
Cardiovascular Contraindication
Vyleesi is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease.
Pregnancy
Use during pregnancy is not recommended. FDA labeling advises effective contraception while taking Vyleesi and discontinuation if pregnancy is suspected.
Oral Medication Absorption
Bremelanotide can slow gastric emptying and may affect absorption of oral medications. FDA specifically advises avoiding oral naltrexone-containing products used for alcohol or opioid addiction because bremelanotide can substantially reduce naltrexone exposure.
What Happens After Administration?
Half-Life Is Not the Same as Duration of Sexual Effect
The pharmacokinetic half-life describes how the drug is cleared from the bloodstream. FDA notes that the duration of efficacy after each dose and the optimal administration window have not been fully characterized.
FDA Approval vs. Broader Sexual-Wellness Interest
Established FDA Use
Acquired, generalized HSDD in premenopausal women who meet the criteria described in the prescribing information.
Other Populations
Bremelanotide has also generated research interest in male sexual function and other sexual-wellness applications, but these are not FDA-approved indications for Vyleesi.
Approved Vyleesi Is a Specific Pharmaceutical Product
The FDA-approved product contains bremelanotide in a standardized 1.75 mg/0.3 mL single-dose autoinjector.
Products marketed or compounded as “PT-141” should not automatically be assumed to have identical formulation, manufacturing, delivery, pharmacokinetics, or regulatory status.
Frequently Asked Questions
Is PT-141 the same as bremelanotide?
PT-141 is the development name commonly associated with bremelanotide. Vyleesi® is the FDA-approved bremelanotide drug product.
Does PT-141 increase testosterone or estrogen?
Bremelanotide is not a testosterone or estrogen replacement therapy. Its primary pharmacology involves melanocortin receptor signaling.
Is PT-141 the same as Viagra?
No. Sildenafil and similar medications primarily influence peripheral vascular pathways involved in erectile function. Bremelanotide acts through melanocortin signaling within the central nervous system.
Is bremelanotide FDA approved for men?
No. Vyleesi is not FDA indicated for men.
Is Vyleesi approved for postmenopausal women?
No. The current FDA indication is specifically for premenopausal women with acquired, generalized HSDD.
Does it work immediately?
The approved product is taken at least 45 minutes before anticipated sexual activity. Individual response varies, and FDA states that the optimal timing and duration of efficacy have not been fully characterized.
Is PT-141 an aphrodisiac?
That term oversimplifies the drug. Bremelanotide is better described as a melanocortin receptor agonist developed to improve sexual desire and reduce distress associated with HSDD in its approved population.
The Bigger Picture
Low sexual desire can have multiple contributors. A complete evaluation may include hormones, medications, sleep, stress, cardiovascular and metabolic health, pain, menopause status, psychological well-being, neurologic function, and relationship context.
A medication can target one biological pathway, but long-term sexual wellness often requires understanding the entire picture.
Sexual Wellness Is More Than Performance
Healthy sexual function involves desire, arousal, physical health, nervous system signaling, hormones, confidence, emotional connection, and overall well-being.
The goal is not simply more sexual activity. It is healthier sexual function.Interested in Sexual Wellness?
Schedule a personalized wellness consultation to discuss sexual desire, hormonal and metabolic health, medications, stress, symptoms, and appropriate treatment options.
Book a Wellness ConsultationSelected Scientific & Clinical References
FDA-approved indication, dosing, mechanism, contraindications, safety, pharmacokinetics, and clinical-trial data for bremelanotide.
View Current Prescribing Information →
Two randomized Phase 3 RECONNECT trials evaluating bremelanotide for hypoactive sexual desire disorder.
View on PubMed →
Long-term safety and efficacy during the 52-week open-label extension of the RECONNECT trials.
View on PubMed →
Phase 2b responder analyses evaluating clinically meaningful responses to bremelanotide.
View on PubMed →
Prespecified subgroup analyses from the Phase 3 RECONNECT bremelanotide program.
View on PubMed →